These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 21830087)
1. 18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response. Ueda S; Saeki T; Shigekawa T; Omata J; Moriya T; Yamamoto J; Osaki A; Fujiuchi N; Misumi M; Takeuchi H; Sakurai T; Tsuda H; Tamura K; Ishida J; Abe Y; Imabayashi E; Kuji I; Matsuda H Int J Clin Oncol; 2012 Jun; 17(3):276-82. PubMed ID: 21830087 [TBL] [Abstract][Full Text] [Related]
2. The role of interim 18F-FDG PET/CT in predicting early response to neoadjuvant chemotherapy in breast cancer. Pahk K; Rhee S; Cho J; Seo M; Lee S; Park T; Park S; Lee E; Park KH; Kim C; Eo JS; Kim S; Choe JG Anticancer Res; 2014 Aug; 34(8):4447-55. PubMed ID: 25075084 [TBL] [Abstract][Full Text] [Related]
3. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Berriolo-Riedinger A; Touzery C; Riedinger JM; Toubeau M; Coudert B; Arnould L; Boichot C; Cochet A; Fumoleau P; Brunotte F Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1915-24. PubMed ID: 17579854 [TBL] [Abstract][Full Text] [Related]
4. HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy. Humbert O; Cochet A; Riedinger JM; Berriolo-Riedinger A; Arnould L; Coudert B; Desmoulins I; Toubeau M; Dygai-Cochet I; Guiu S; Coutant C; Fumoleau P; Brunotte F Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1525-33. PubMed ID: 24647576 [TBL] [Abstract][Full Text] [Related]
5. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer? Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422 [TBL] [Abstract][Full Text] [Related]
6. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment. Groheux D; Giacchetti S; Hatt M; Marty M; Vercellino L; de Roquancourt A; Cuvier C; Coussy F; Espié M; Hindié E Br J Cancer; 2013 Sep; 109(5):1157-64. PubMed ID: 23942075 [TBL] [Abstract][Full Text] [Related]
7. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404 [TBL] [Abstract][Full Text] [Related]
8. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914 [TBL] [Abstract][Full Text] [Related]
9. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer. Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821 [TBL] [Abstract][Full Text] [Related]
10. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218 [TBL] [Abstract][Full Text] [Related]
11. Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. Jacobs MA; Ouwerkerk R; Wolff AC; Gabrielson E; Warzecha H; Jeter S; Bluemke DA; Wahl R; Stearns V Breast Cancer Res Treat; 2011 Jul; 128(1):119-26. PubMed ID: 21455671 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441 [TBL] [Abstract][Full Text] [Related]
13. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype. Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099 [TBL] [Abstract][Full Text] [Related]
14. Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer. García Vicente AM; Cruz Mora MÁ; León Martín AA; Muñoz Sánchez Mdel M; Relea Calatayud F; Van Gómez López O; Espinosa Aunión R; Gonzalez Ageitos A; Soriano Castrejón A Tumour Biol; 2014 Nov; 35(11):11613-20. PubMed ID: 25139100 [TBL] [Abstract][Full Text] [Related]
15. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ BMC Cancer; 2011 Oct; 11():452. PubMed ID: 22011459 [TBL] [Abstract][Full Text] [Related]
16. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer. Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896 [TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954 [TBL] [Abstract][Full Text] [Related]
18. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368 [TBL] [Abstract][Full Text] [Related]
19. Subtype-Guided Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448 [TBL] [Abstract][Full Text] [Related]
20. Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. Park SH; Moon WK; Cho N; Chang JM; Im SA; Park IA; Kang KW; Han W; Noh DY Eur Radiol; 2012 Jan; 22(1):18-25. PubMed ID: 21845462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]